Repligen RGEN 深 滬
等待開盤 11-04 09:30:00 美东时间
150.17
+1.110
+0.74%
華盛通- 最 高150.84
- 今 開147.52
- 成交量 77.06万股
- 最 低 146.42
- 昨 收 149.06
- 總市值 84.48亿
- 52周最高 182.52
- 市盈率 靜 --
- 換手率 1.37%
- 52周最低 102.965
- 委 比 74.33%
- 總股本 5625.76万
- 歷史最高 327.32
- 量 比 0.58
- 振 幅 2.97%
- 歷史最低 2.90
- 每 手 1
- 風險率 15.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Preview For Bruker
Bruker (NASDAQ:BRKR) is gearing up to announce its quarterly earnings on Monday...
11-01 00:02
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Barclays Maintains Overweight on Repligen, Raises Price Target to $175
Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $160 to $175.
10-29 21:32
Repligen Narrows FY2025 Adj EPS Guidance from $1.65-$1.72 to $1.65-$1.68 vs $1.68 Est; Raises FY2025 Sales Guidance from $715.000M-$735.000M to $729.000M-$737.000M vs $726.458M Est
Repligen (NASDAQ:RGEN) narrows FY2025 Adj EPS guidance from $1.65-$1.72 to $1.65-$1.68 vs $1.68 analyst estimate. Raises FY2025 sales outlook from $715.000 million-$735.000 million to $729.000 million-$737.000 million vs
10-28 19:31
Repligen Q3 Adj. EPS $0.46 Beats $0.42 Estimate, Sales $188.805M Beat $181.338M Estimate
Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.42 by 10.05 percent. This is a 6.98 percent increase over earnings of $0.43 per share from the same
10-28 19:30
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
10-28 19:11
优然牧业赛科星再添全球最先进新款性控分离机，总装机量达15台，领跑行业！
科技赋能 近期，优然牧业赛科星迎来了重大利好消息，公司成功从美国引进了全球最先进的新款性控分离机。这是国内落地的第一台也是公司拥有的第15台性控分离机，进一步巩...
10-10 17:10
SKYX Platforms Raises Additional $3.25M Investment From Current Lead Investor
MIAMI, Oct. 09, 2025 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the "Company" or "SKYX"), a highly disruptive platform technology company with over 100 pending and issued patents
10-09 23:04
What's Going On Sarepta Stock On Wednesday?
Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week.
10-08 23:19
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
